Jawa International Seeks ₦3 Billion. What Can Working Capital Become Inside a Drug Company?
DA-X59 · Healthcare · By David Adeniji ·
Jawa International is seeking ₦3 billion through commercial paper to finance working capital. In pharmaceuticals, that money can travel through ingredients, packaging, production, inventory and distribution.
Today's Signal
Jawa International Limited has opened a ₦3 billion Series II commercial paper under its ₦10 billion programme, with proceeds earmarked for working-capital requirements. The offer closes September 15, with issue and settlement scheduled for September 16.
Money Direction
Investors → ₦3 billion Jawa commercial paper → working capital → pharmaceutical inputs, packaging, production and inventory → distributors and pharmacies → medicine sales and cash generation.
Opportunity Areas
Pharmaceutical manufacturing; active ingredients and other inputs; packaging; healthcare distribution; logistics; warehousing; pharmacies; procurement; manufacturing support services and working-capital finance.
Skills Signal
Pharmacy, pharmaceutical production, quality control, quality assurance, procurement, supply-chain management, warehousing, sales, distribution, finance, treasury and manufacturing operations.
Who Should Pay Attention
Pharmaceutical suppliers, packaging companies, healthcare distributors, logistics businesses, pharmacists, production technicians, procurement professionals, finance professionals, job seekers, investors and Nigerian manufacturers managing expensive working capital.
Watching Next
Final subscription and allotment, actual amount raised, September 16 settlement, how Jawa deploys the working capital and whether financing translates into higher production, inventory, distribution or employment.
DA-X59: ₦3 billion is heading toward a Nigerian pharmaceutical company — but the interesting part is what working capital can become.
Jawa International has opened a ₦3bn Series II commercial paper under its ₦10bn programme. The 270-day note offers a 23.8178% yield and closes September 15. Jawa says the proceeds will finance working-capital requirements.
“Working capital” sounds boring. In a pharmaceutical business, it isn't.
It can mean buying active ingredients and packaging, keeping production lines running, holding inventory and moving medicines through distributors before customers pay.
Follow that chain and ₦3bn can touch chemical and packaging suppliers, transporters, warehouses, pharmacies and healthcare distribution. It can also support demand for pharmacists, production technicians, quality-control professionals, procurement officers, sales teams and supply-chain managers.
Jawa has operations across Nigeria's six geopolitical zones, and BOI has previously supported its manufacturing and nationwide expansion.
But here is the contrast: investors are being offered almost 24% annualised yield. That tells you capital is available, but it is not cheap.
For Jawa, the test is whether the operating return generated with this short-term money outruns its financing cost. For manufacturers, that is the lesson too: raising money is only half the job.
And ₦3bn offered is not ₦3bn raised. The offer is still open. Settlement is scheduled for September 16.
So I am watching two numbers next: how much investors actually provide, and what Jawa's working-capital cycle turns it into.
Money can buy medicine inputs. Good execution turns those inputs into cash, growth and jobs.
Sources
Proshare Bank of Industry